| P2093 | author name string | Kaoru Mori | |
| | Sakae Tanaka | |
| | Naoyuki Takahashi | |
| | Nobuyuki Udagawa | |
| | Hisataka Yasuda | |
| | Tadashi Ninomiya | |
| | Yuriko Furuya | |
| | Yoshiya Tomimori | |
| | Kohji Uchida | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 |
| | Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis | Q24324701 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 |
| | Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor | Q28142274 |
| | Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system | Q28283972 |
| | RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee | Q29616160 |
| | A novel molecular mechanism modulating osteoclast differentiation and function | Q30643494 |
| | The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys | Q33279942 |
| | Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. | Q33385262 |
| | Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. | Q34107428 |
| | Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro | Q34459310 |
| | Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. | Q34469691 |
| | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women | Q34912769 |
| | Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression | Q35169193 |
| | Regulation of cancer cell migration and bone metastasis by RANKL. | Q40298349 |
| | Control of mammary stem cell function by steroid hormone signalling. | Q43103606 |
| | Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL. | Q46030946 |
| | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats | Q46099755 |
| | A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women | Q46133598 |
| | Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. | Q46459616 |
| | Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone | Q46635832 |
| | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | Q46699294 |
| | The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. | Q51949099 |
| | Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. | Q52542731 |
| | Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody | Q79826358 |
| P433 | issue | 42 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 37023-37031 | |
| P577 | publication date | 2011-08-23 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts | |
| P478 | volume | 286 | |